Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate ...
UnitedHealth Group appoints Dr. Scott Gottlieb to its board, enhancing leadership amongst a time in which the company looks ...
Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...
Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to ...
Artificial intelligence is a wildcard in the selection process, most profoundly in its agentic form. AI agents 2 will help ...
The FDA’s new Commissioner’s National Priority Voucher signals a transformative shift in U.S. drug review, tying accelerated approval to manufacturing readiness, domestic supply-chain strength, and ...
PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...
Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their ...
Stanton’s research, including the 2023 HBS case “Generative AI and the Future of Work,” underscores a pivotal truth: AI will not eliminate jobs en masse in the near term, but it will reshape them, ...
Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and ...
Olympia Pharmaceuticals expanded into Mississippi, now licensed in 49 states, enhancing access to compounded pharmaceuticals and manufacturing capabilities. The company's strategy emphasizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback